Literature DB >> 11498396

Atovaquone resistance in malaria parasites.

Akhil B. Vaidya1, Michael W. Mather.   

Abstract

Atovaquone is a broad-spectrum antiparasitic agent active against malaria, Pneumocystis carinii pneumonia, toxoplasmosis and babesiosis. When used as a single agent, resistance to atovaquone arose rapidly in falciparum malaria, requiring the development of a new antimalarial drug combination of atovaquone and proguanil. Recent laboratory investigations have provided insights into the mode of atovaquone action, and identified the molecular basis for the resistance development. Mutations within a catalytic domain of the cytochrome bc(1)complex present within the parasite mitochondrial inner membrane were shown to be responsible for atovaquone resistance. Here, we review these studies and propose a mechanism by which atovaquone resistance may arise quickly in malaria parasites. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Year:  2000        PMID: 11498396     DOI: 10.1054/drup.2000.0157

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  31 in total

Review 1.  Classical and alternative components of the mitochondrial respiratory chain in pathogenic fungi as potential therapeutic targets.

Authors:  Vicente de Paulo Martins; Taisa Magnani Dinamarco; Carlos Curti; Sérgio Akira Uyemura
Journal:  J Bioenerg Biomembr       Date:  2011-02       Impact factor: 2.945

2.  High-throughput Plasmodium falciparum growth assay for malaria drug discovery.

Authors:  Mary Lynn Baniecki; Dyann F Wirth; Jon Clardy
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  The mitochondrial ribosomal protein L13 is critical for the structural and functional integrity of the mitochondrion in Plasmodium falciparum.

Authors:  Hangjun Ke; Swati Dass; Joanne M Morrisey; Michael W Mather; Akhil B Vaidya
Journal:  J Biol Chem       Date:  2018-04-06       Impact factor: 5.157

4.  Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones.

Authors:  Louise M Hughes; Raul Covian; Gordon W Gribble; Bernard L Trumpower
Journal:  Biochim Biophys Acta       Date:  2009-08-04

5.  Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.

Authors:  Allison M Stickles; Martin J Smilkstein; Joanne M Morrisey; Yuexin Li; Isaac P Forquer; Jane X Kelly; Sovitj Pou; Rolf W Winter; Aaron Nilsen; Akhil B Vaidya; Michael K Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Genetic ablation of the mitoribosome in the malaria parasite Plasmodium falciparum sensitizes it to antimalarials that target mitochondrial functions.

Authors:  Liqin Ling; Maruthi Mulaka; Justin Munro; Swati Dass; Michael W Mather; Michael K Riscoe; Manuel Llinás; Jing Zhou; Hangjun Ke
Journal:  J Biol Chem       Date:  2020-04-09       Impact factor: 5.157

Review 7.  Drug-resistant malaria.

Authors:  John E Hyde
Journal:  Trends Parasitol       Date:  2005-09-02

8.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

9.  Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria.

Authors:  Quinton L Fivelman; Geoffrey A Butcher; Ipemida S Adagu; David C Warhurst; Geoffrey Pasvol
Journal:  Malar J       Date:  2002-02-08       Impact factor: 2.979

Review 10.  The interplay between drug resistance and fitness in malaria parasites.

Authors:  Philip J Rosenthal
Journal:  Mol Microbiol       Date:  2013-08-16       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.